Presenting Companies
Acorai is developing a non-invasive point-of-care device for heart failure management. The device estimates cardiac and pulmonary pressures at the bedside in under five minutes. It is designed to help clinicians make better decisions on admission, decongestion, discharge, and follow-up. Acorai has generated clinical validation data against right heart catheterization and is advancing toward FDA clearance.
Araceli Biosciences is revolutionizing drug discovery and clinical diagnostics with its ultra-high-throughput imaging platform and AI-powered analysis software. Designed to accelerate data generation and analysis, Araceli empowers drug discovery approaches with iterative AI based Lab-in-a-Loop workflows. Araceli is the only imaging solution on the market that can generate data and agentic AI feedback needed for the new paradigm AI driven drug discovery.
brain4care monitors intracranial dynamics, including variation of intracranial pressure (ICP), progression of intracranial compliance and early assessment of intracranial hypertension.
The Breast Cancer Locator (BCL) is a proprietary patient-specific 3-D printed guide designed to enable more precise tumor excision and thus fewer re-excisions. The BCL provides information regarding tumor size, shape, and clear margin boundary to help surgeons completely excise the cancer and preserve normal breast tissue. CairnSurgical provides a wrap-around service for the surgeon and patient with the BCL. The Company receives MRI data, analyzes it to define tumor geometry and location, and uses the data to fabricate the BCL and provide an interactive 3-D Visualizer. Clinical trials (both single arm and randomized) have shown dramatic and statistically significant reductions in the re-excision rate when using the BCL. FDA submission is complete; clearance is pending.
CaroRhythm is developing CaroSense, a non-invasive wearable medical device that sits over the neck and continuously monitors changes in blood flow and embolic activity through the carotid arteries - two key signs of stroke onset. Stroke survivors wear the device for the 2-4 weeks after they leave the hospital following a stroke event, which is the time period when they are at the highest risk of stroke recurrence and when clinical support is at its lowest due to inconsistent follow ups and monitoring. CaroSense uses diffuse optical tomography to image vascular changes that precede or result from an ischemic stroke. The accompanying software platform provides survivors, caregivers, and clinicians with real-time updates on a survivor’s vascular health and stroke risk. CaroRhythm was founded as a spin-off from the NYU Clinical Biophotonics Lab to make objective cerebrovascular monitoring available outside the hospital for the first time and provide life-saving insights to patients, payors, and providers.
CleanMargin is a clinical-stage company developing the proprietary fluorescent surgical imaging agent, MarginVue, that enables surgeons to precisely visualize and remove all cancer lesions during breast-conserving cancer surgery to achieve clean (cancer-free) surgical margins, which is a large unmet medical need in breast cancer and many other cancer surgeries. Our ongoing Phase II clinical trials conducted at Memorial Sloan Kettering Cancer Center together with our device partner, Stryker Corp., demonstrate that MarginVue is safe and detects all sub-types of breast cancer with 100% sensitivity – a significant improvement over the performance of other competing imaging agents or devices.
Coagulation Sciences’ fully automated Multiple Coagulation Test System (MCTS™) performs 18 advanced coagulation blood tests, in a disposable cartridge, at the Point-of-Care. Easy to interpret results, displayed in ~ 10 minutes, will guide physicians to optimally manage bleeding patients and blood transfusion decisions. By using the MCTS™ hospitals in the US+EU will save $24B annually that will flow directly to their bottom line. It will also improve patient outcomes, as the 45% rate of unnecessary and harmful blood transfusions will be minimized.
Cognixion is pioneering the next generation of communication through a noninvasive brain-computer interface (BCI) platform that enables individuals with severe speech and motor impairments to communicate and engage with the world. By combining advanced neurotechnology, artificial intelligence, eye tracking, and spatial computing, Cognixion transforms user intent into meaningful communication and control without the need for surgical implants. The company's technology is designed to serve individuals affected by ALS, stroke, spinal cord injury, traumatic brain injury, and other neurological conditions. Cognixion's vision extends beyond assistive technology to a future where seamless brain-driven interaction becomes a new paradigm for digital access and communication.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Faex Health is an AI-powered digital health company transforming gut health monitoring through computer vision and advanced analytics. Our platform enables users to capture a simple image of their stool and receive personalized insights into digestive health, helping identify trends and potential concerns over time. By turning an underutilized health indicator into actionable data, Faex aims to improve preventive care, support earlier detection of health issues, and empower individuals to take a more proactive approach to their wellbeing. Through partnerships with healthcare providers, researchers, and digital health organizations, Faex is building the future of accessible gut health intelligence.
Immunicom is developing a non-drug-based cancer therapy with the potential to reduce treatment side effects, enhance therapy response rates and improve cancer patients’ quality of life – all at significantly lower costs and without the side effects and complications prevalent in existing immunotherapy approaches. Immunicom's cancer therapy has the potential to allow the body’s natural immune system to directly attack the cancer while enhancing the effects of other cancer treatments which may be used concurrently.
Kilele’s wearable biosensor platform enables precision medicine by bringing real-time molecular insights into everyday care. Our painless sensor is worn for two weeks at a time, mimics the form factor and UI/UX of proven continuous glucose monitoring devices, and can measure up to 5 blood chemistry parameters at once. Applications include chronic disease management, therapeutic drug monitoring, and continuous hormone monitoring. We begin human testing in our core cardiometabolic health markets this summer, starting with a phenylalanine sensor for phenylketonuria (PKU) and GLP-1 associated sarcopenia management; next up will be sensors for cardiorenal and diabesity use cases.
MedCube is transforming the €24 billion global medical transport industry from fragmented coordination into an intelligent operational network. The platform connects insurers, assistance companies, healthcare providers and transport operators in a shared workflow, serving as both the system-of-record and system-of-work for a market that repatriates 4 million patients annually. By capturing workflow, data and decision logic across the ecosystem, MedCube creates the foundation for optimisation, automation and AI-driven orchestration at global scale. The company is led by a team of experienced medical transport, assistance and SaaS operators who have spent decades managing the workflows they are now transforming.
.jpg){kind=logo}
MedOrion is the AI-based operating platform that health plans use to improve quality performance, member experience, medication adherence, and revenue at scale. By continuously fusing clinical, situational, and behavioral signals, MedOrion's adaptive intervention engine identifies what is blocking each member from acting and automatically executes the right outreach at the right time and through the right channel. The platform replaces fragmented point solutions with a unified quality execution layer spanning measure strategy, personalized member journeys, and native third-party integrations. Deployed with leading national and regional plans and actively managing the care journeys of approximately 6 million Medicare Advantage members, MedOrion is delivering measurable improvements across clinical quality, member experience, and medication adherence measures, tied to an estimated $100M+ in economic impact for its customers.
Microvascular Therapeutics is a clinical stage biotechnology which pioneers in ultrasound contrast agents and theranostics. Microvascular Therapeutics (MVT) is developing a new improved ultrasound contrast agent MVT-100 via the 505(b)(2) pathway. The founders of MVT developed Definity®, the world’s #1 selling ultrasound contrast agent. Definity requires refrigerated temperature storage and has side effect of back pain. MVT-100 is a room temperature storage product and designed to eliminate the back pain. MVT has multiple theranostic products in its pipeline with multi-billion dollar market potential, the first one of which is expected to be regulated via the device pathway.
MindBio has developed an AI model that uses Voice signal recognition as a biomarker to predict drug and alcohol intoxication and fatigue. The Company's Edge AI Intoxication and Fatigue Detection Kiosks are a world first product designed for the mining, aviation, construction and heavy transport industries to detect drug and alcohol use and fatigue for improved safety and reduced accidents.
Neuroloop’s mission is to set new standards in treating chronic diseases by replacing drugs with electricity – especially where pharmacological treatments are limited or have failed. Thus, we developed an implantable neurostimulator platform based on advanced thin-film technology, enabling smart, selective stimulation of the vagus nerve. The first indication we are focusing on within our product pipeline is true resistant hypertension.
New View Medical is a medical technology company pioneering surgeon-controlled visualization in minimally invasive surgery through its VisionPort™ platform. VisionPort™ is a single-use integrated laparoscopic port that combines visualization, illumination, and access into one device — consolidating what traditionally required separate camera and access systems into a streamlined surgeon-controlled platform at the point of entry. The technology is designed to simplify OR workflow, reduce setup and turnover time, free clinical staff from camera-holding duties, and potentially reduce the number of ports required during surgery. Following FDA clearance of its first-generation device and successful in-vivo validation, the company is advancing its next-generation system focused on enhanced imaging performance, improved economics, and broader procedural applicability within the growing laparoscopic surgery market.
Noah Labs has developed NL Vox, a patented, FDA Breakthrough-designated software medical device that analyzes subtle vocal biomarker changes caused by pulmonary fluid buildup in heart failure patients. Using deep learning models trained on the world's largest proprietary dataset of over 3 million labeled voice samples, NL Vox delivers over 84% sensitivity, matching invasive implant-level precision at a fraction of the cost.The platform integrates seamlessly into clinical workflows, alerting clinicians when heart failure decompensation is detected to enable early medical intervention. Noah Labs also operates Noah Labs Ark, a revenue-generating Class IIa remote patient monitoring platform deployed across 150+ clinics in Germany, forming the clinical and data foundation for NL Vox's US expansion.
Omniscient is a global leader in the field of connectomics, using AI and MRI technology to map and analyze the brain’s intricate network of connections. Omniscient’s FDA-cleared platform, Quicktome®, provides clinicians with critical insights to guide prognosis and treatment across a range of neurological conditions. Looking ahead, Omniscient’s technology stands to transform brain health by enabling truly personalized care for patients impacted by Alzheimer’s, stroke, depression, and beyond.
PredxBio is a clinical decision intelligence company developing SpaceIQ™, an AI software platform that turns tumor tissue biology into reusable decision models for oncology drug development. We partner with leading biopharma companies to reduce late-stage failure risk and improve patient stratification by embedding mechanistic, reusable decision models across clinical programs. By revealing which patients are most likely to respond, why resistance emerges, and how tissue biology can guide biomarker strategy, SpaceIQ™ helps translate complex spatial biology into clinically meaningful development decisions. With validated clinical traction, early SaaS expansion, and a strong IP foundation, PredxBio is building the enterprise decision layer for spatial biology.
Rainfall Health is the first and only AI-powered accountability and accessibility platform providing thought and technology leadership to health systems. Our technology automates compliance, augments care coordination, and delivers AI-enabled care design — helping health systems avoid penalities and capture a combined $19Bn in new Medicare revenue. We are the first and only product-based enterprise solution that is a recognized standard for Medicare-mandated models such as TEAM and CJR-X, affecting over 3,100 hospitals nationwide. Rainfall is a high-growth SaaS company at the forefront of value-based care enablement, capitalizing on long-standing trends to reduce healthcare expenditures and waste while improving patient outcomes. Led by a team of passionate healthcare executives, clinical experts, and technology leaders, we are scaling rapidly to ensure better healthcare for all Americans.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of TETRANITE®, a patented, regenerative bone glue for a range of clinical applications in the cranial, dental, orthopaedics, spinal, and animal health markets. Founded in 2014, RevBio was started with one goal in mind—to end medicine’s fifty-year search for a regenerative bone adhesive.
SAGE has developed a highly effective approach to identify the best treatment for cancer patients that overcomes the inherent limitations of genomic testing. This is accomplished by creating 3D microtumor replicates from a fresh tissue biopsy that reflect the patient tumor's heterogeneity and extracellular matrix.
The demand for large-bore access to the femoral artery is increasing rapidly with rise of procedures like Transcatheter Aortic Valve Replacement (TAVR), Percutaneous Endovascular Aortic Aneurysm Repair (PEVAR), and Cardiac Support with Percutaneous Ventricular Assist Device (pVAD). Many of these patients will require additional procedures in their lifetime such Valve-in-Valve TAVR and/or coronary interventions which require an unobstructed access to the femoral artery. We are developing QuattroClose—Ultilizing Halo-Lock ™ which will support the patients’ lifetime management even in challenging calcified arteries.
Transverse Medical Inc. is developing the POINT-GUARD® PRO Cerebral Embolic Protection medical device to address the unmet need for Full Brain Protection and the clinical problem of periprocedural Stroke in Structural Heart Procedures, such as Transcatheter Aortic Valve Replacement (TAVR). The Point-Guard PRO medical device is designed to minimize incremental procedure time and physician ease-of-use, in addition to providing maximum filter coverage with an innovative asymmetric design. The innovative technology is designed with ability to provide a simplified, cost efficient, TAVR-compatible solution for full brain protection of the patient’s brain during TAVR, which distinguishes the POINT-GUARD® PRO from other CEPs in development and the partial protection Sentinel device (the only FDA approved device).
Unify Medical is a privately funded medical technology company dedicated to developing advanced wearable digital systems that display dynamically magnified 3D images in high-definition. Unify Medical has just launched SurgiSight™, the world’s first wearable surgical microscope providing groundbreaking visualization in a form factor and cost basis unavailable in current microscopy solutions. The device was selected "TIME’s Best Inventions for 2024".
Vascudyne, Inc. is a clinical-stage medtech company commercializing the first bioengineered tissue implants for cardiovascular surgery, a 50 billion dollar market with no approved regenerative device today. The company's lead product, a bioengineered coronary artery bypass graft, has demonstrated zero adverse events through 18 months in human implants and is actively enrolling in a multi-site clinical study, with results published in the Journal of the American College of Cardiology. Two additional programs, a pediatric vascular conduit and a bioengineered heart valve, address large, underserved patient populations where existing synthetic and donor-tissue solutions carry well-documented limitations in durability, infection risk, and pediatric sizing. Vascudyne has closed a $35 million Series B and secured over $10 million in non-dilutive DoD funding, and is now raising capital to advance its Phase 2 CABG trial and Phase 1 heart valve program.
VoluMetrix is developing NIVAHF, a non-invasive device to measure intravascular volume status in heart failure patients using a simple wrist sensor; no implants, no catheterization. The device captures venous waveforms and delivers results as a clear numeric measurement suitable for hospital, clinic, or home use, addressing a critical gap in a market driving over $10B in annual hospital costs. VoluMetrix holds FDA Breakthrough Device Designation and has 510 (k) clearance targeted for Q1 2027.